ABSTRACT
Infections are increasingly recognized as a common complication of chimeric antigen receptor (CAR) T-cell therapy. The incidence of clinically-defined infection after CD19.CAR T-cell therapy for relapsed/refractory lymphoma ranges from 60-90% in the first year after CAR T-cell therapy and is the most common cause for non-relapse mortality. However, infectious risk after CAR T-cell therapy targeting other malignancies is not well understood. Herein, we report for the first time, infectious complications after CD30.CAR T-cell treatment for patients with Hodgkin’s lymphoma and peripheral T-cell lymphoma. Since CD30 is only expressed on a subset of activated T and B-cells, we hypothesized that CD30.CAR T-cell patients would have reduced incidence and severity of infections after infusion compared to CD19.CAR T-cell patients. We retrospectively evaluated all 64 patients who received CD30.CAR T-cells at a single institution between 2016-2021, and assessed infections within one year after cell infusion, comparing these data to a contemporary cohort of 50 patients who received CD19.CAR T-cells at the same institution between 2018-2021. 23 CD30.CAR T-cell patients (36%) and 18 CD19.CAR T-cell patients (36%) developed a microbiologically confirmed infection. Infection severity and bacterial infections were higher in the CD19.CAR T-cell group compared to CD30.CAR T-cell recipients who more commonly had grade 1 respiratory viral infections. Our data reflect expected outcomes for severity and infection type in CD19.CAR T-cell patients and provide a benchmark for comparison with the novel CD30.CAR T-cell product. Although our findings require replication in a larger cohort, they have implications for antimicrobial prophylaxis guidelines after CD30.CAR T-cell therapy.
KEY POINTS
1) The incidence of infections within the first year after CD30.CAR T-cell therapy was equivalent to that following CD19.CAR T-cell therapy
2) Viral infections were more common after CD30.CAR T-cell therapy but bacterial infections predominated after CD19.CAR T-cell therapy.
Competing Interest Statement
J.S.S. has IP for the use of ILC2 cells to treat and prevent GVHD and for the use of STING agonists to enhance CAR T-cell function; he receives royalty payments from Tessa Therapeutics for the CD30.CAR T-cell product. G.D. has acted as a consultant of Bellicum Pharmaceutical and Tessa Therapeutics, serves as a consultant for Catamaran, and has pending patents in the field of CAR T-cells. M.K.S. receives honoraria from Calliditas, Travere, ChemoCentryx, and Elsevier. B.S. acted as a consultant of Tessa Therapeutics. N.S.G. has served on an advisory board or consulted for Novartis, Kite, Seagen, ADC Therapeutics, BMS, and Caribou Biosciences. T.M.A. serves as a consultant for Seres Therapeutics. Otherwise, the remaining authors declare no conflicts of interest.
Funding Statement
F.C. is funded by National Cancer Institute UNC Immunotherapy Training Grant T32 1T32CA28527-01. MM is funded by the Infectious Disease Society of America Grants for Emerging Researchers (G.E.R.M). TMA is funded by the Amy Strelzer Manasevit/Be The Match Foundation Award, a K23 NIAID/NIH Career Development Award (AI163365), and the UNC Center for Gastrointestinal Biology and Disease pilot award. REDCap use was made possible through grant UL1TR002489 from the Clinical and Translational Science Award program of the Division of Research Resources, NIH. J.S.S. is supported by R01 155098 from NHLBI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was obtained from the University of North Carolina Chapel Hill institutional review board (IRB#20-2745, PI: Andermann).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
